Cancer Clinical Trial - Salarius SALA-003-AC19

Status:

Open

ClinicalTrials.gov:

NCT03895684

CONDITION(S): Advanced Solid Tumors - TRIAL: Salarius SALA-003-AC19 - Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.

Drug

SP-2577 Seclidemstat

Trial Type

Interventional

Phase

Phase 1

Condition

Advanced solid tumors

Keywords

Advanced solid tumors | SP-2577 Seclidemstat